WHO and Gilead Sciences renew partnership to accelerate visceral leishmaniasis elimination

The World Health Organization (WHO) and Gilead Sciences have renewed their partnership through a new five-year agreement (2026–2030) to support the elimination of visceral leishmaniasis (VL), a life-threatening neglected tropical disease.

Under the agreement, Gilead Sciences will donate 402 941 vials of AmBisome (liposomal amphotericin B for injection) to treat visceral leishmaniasis and its complications in countries most affected by the disease. Gilead Sciences started donating this medicine to WHO in 2012, and the agreement has since been extended three times.